A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Part of paid clinical trials in Sacramento, California.

Sponsor
Eli Lilly and Company
Study ID
NCT07668336
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
10 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.

Key Dates

Start date
Sep 30, 2026
Status verified
Jun 2026
Primary completion
Mar 31, 2030
Completion
Mar 31, 2030

Study Design

Enrollment
170 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Orforglipron
    Participants will receive orforglipron orally
  • Active Comparator: Dulaglutide
    Participants will receive dulaglutide subcutaneously (SC)

Primary Outcome Measure

Change from Baseline in Hemoglobin A1c (HbA1c) [ Time Frame: Baseline, Week 40 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (17)

FacilityCityStateZIPSite coordinators
Sutter Valley Medical Foundation (SVMF) Pediatric EndocrinologySacramentoCalifornia95821
916-426-1902
Gnanagurudasan Prakasam (PRINCIPAL_INVESTIGATOR)
Rady Children's HospitalSan DiegoCalifornia92123
858-966-8940
Carla Demeterco-Berggren (PRINCIPAL_INVESTIGATOR)
Stamford Therapeutics ConsortiumStamfordConnecticut06905
David Radin (PRINCIPAL_INVESTIGATOR)
Children's Healthcare of Atlanta - Center for Advanced Pediatrics (CAP)AtlantaGeorgia30329-
CenExel iResearch, LLCDecaturGeorgia30030
404-537-1281
Kimball Johnson (PRINCIPAL_INVESTIGATOR)
Medical Research PartnersAmmonIdaho83406
208-522-4600
Mitchael Steorts (PRINCIPAL_INVESTIGATOR)
Cotton O'Neil Diabetes & EndocrinologyTopekaKansas66606
785-354-9591
susan brian (PRINCIPAL_INVESTIGATOR)
SUNY Upstate Medical UniversitySyracuseNew York13210-
Advantage Clinical TrialsThe BronxNew York10467
917-962-0234
Giancarlo Guido (PRINCIPAL_INVESTIGATOR)
Central States ResearchTulsaOklahoma74136
918-645-5400
Sarah Land (PRINCIPAL_INVESTIGATOR)
Frontier Clinical Research, LLCSmithfieldPennsylvania15478
724-569-8036
Marcy Goisse (PRINCIPAL_INVESTIGATOR)
Vanderbilt Health One Hundred OaksNashvilleTennessee37204
225-226-5662
Gitanjali Srivastava (PRINCIPAL_INVESTIGATOR)
Gadolin ResearchBeaumontTexas77702
409-331-6040
John Fowler (PRINCIPAL_INVESTIGATOR)
Driscoll Children's HospitalCorpus ChristiTexas78411
361-739-7250
Ana Paez (PRINCIPAL_INVESTIGATOR)
Proactive Clinical Research LLCEdinburgTexas78539
956-731-1260
Gerardo Orfanos (PRINCIPAL_INVESTIGATOR)
Consano Clinical Research, LLCShavano ParkTexas78231
210-545-4900
Michelle Welch (PRINCIPAL_INVESTIGATOR)
Victoria Clinical Research GroupVictoriaTexas77901
361-210-7869
John Clinton (PRINCIPAL_INVESTIGATOR)

Find similar trials in Sacramento, CA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology· Sacramento, CARady Children's Hospital· San Diego, CAStamford Therapeutics Consortium· Stamford, CTChildren's Healthcare of Atlanta - Center for Advanced Pediatrics (CAP)· Atlanta, GACenExel iResearch, LLC· Decatur, GAMedical Research Partners· Ammon, ID

Related Studies